Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Seeing is believing – the problem of blinding in psychological research

    Research output: Contribution to journalLetter

  2. Should antidepressants be used for major depressive disorder?

    Research output: Contribution to journalReviewpeer-review

  3. Statins for primary prevention: what is the regulator's role?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Assessing assumptions for statistical analyses in randomised clinical trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine

    Research output: Contribution to journalEditorialpeer-review

  2. Clinical relevance assessment of animal preclinical research (RAA) tool: development and explanation

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder with estimated global prevalence rates between 3% and 5% in children and 2.5% in adults, depending on the classification system used. The psychostimulant methylphenidate is one of the most frequently used medications for ADHD. In this analysis article we describe shortly the evidence in the field, an application for inclusion of methylphenidate on the WHO Model List of Essential Medicines, the comments raised to the application and the WHO Expert Committee's decision. The application of getting methylphenidate on the WHO list was overzealous in reporting potential benefits, without highlighting key uncertainties and harms. Decisions encompassing medicines candidate to the WHO Model List should not be based on speculation about potential benefits and should fully incorporate areas of uncertainties. Even though methylphenidate has been used for over 60 years, the evidence concerning the benefits of this medication in children, adolescents and adults with ADHD is uncertain. The decision of the committee was to not include methylphenidate in the WHO Model List of Essential Medicines 'due to uncertainties in the estimates of benefit, and concerns regarding the quality and limitations of the available evidence for both benefit and harm'.

Original languageEnglish
JournalBMJ Evidence-Based Medicine
Publication statusE-pub ahead of print - 2021

    Research areas

  • adult psychiatry, child & adolescent psychiatry, psychiatry

ID: 59736352